Post-chemotherapy laparoscopic retroperitoneal lymph node dissection in low volume residual germ cell cancer. A technique to reduce morbidity

被引:0
|
作者
Aufderklamm, S. [1 ]
Todenhoefer, T. [1 ]
Hennenlotter, J. [1 ]
Gakis, G. [1 ]
Mischinger, J. [1 ]
Mundhenk, J. [1 ]
Germann, M. [1 ]
Stenzl, A. [1 ]
Schwentner, C. [1 ]
机构
[1] Univ Tubingen, Urol Klin, D-72076 Tubingen, Germany
来源
UROLOGE | 2013年 / 52卷 / 08期
关键词
Testicular cancer; Morbidity; operative; Space-occupying lesion; persisting; Chemotherapy; platinum-based; Resection; bilateral; TESTIS CANCER; ADJUVANT CHEMOTHERAPY; STAGE-I; TUMOR; LYMPHADENECTOMY; COMPLICATIONS; METASTASES;
D O I
10.1007/s00120-013-3133-5
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Retroperitoneal lymph node dissection (RPLND) is the most appropriate method for the detection of residual tumor tissue and mature teratoma after chemotherapy in patients with advanced nonseminomatous (NSGCT) or seminomatous (SGCT) germ cell tumors in clinical stage II-III. Open surgical procedures are associated with higher morbidity rates and laparoscopic RPLND offers a minimally invasive procedure with equivalent oncological safety and low morbidity. In 39 patients laparoscopic RPLND (L-RPLND) after platinum-based chemotherapy for clinical stage IIa-III NSGCT was performed unilaterally as well as bilaterally by two surgeons. Patients with retroperitoneal residual tumor > 1 cm and normalization of tumor markers after chemotherapy were included. Bilateral L-RPLND was performed with complete contralateral nerve sparing while the decision for ipsilateral nerve preservation was based on the volume of the residual mass in the respective standard field. The L-RPLND was completed in all patients without conversion. Median operation time was 248 min (range 95-397 min) and mean hospitalization time was 5 days (range 3-14 days). Furthermore, there was no difference in recurrence rate of the disease (p=0.45) between patients with unilateral or bilateral dissection. The postoperative ejaculatory function was normal in 37 out of 39 patients. The median follow-up period was 18.5 months (range 3-38 months) and 3 out of 39 patients developed recurrence (7.69 %). Post-chemotherapy L-RPLND is feasible with a lower complication rate and an adequate oncological safety and functional outcome. Due to the complexity of L-RPLND the procedure remains limited to institutions with extensive laparoscopic experience.
引用
收藏
页码:1097 / 1103
页数:7
相关论文
共 50 条
  • [21] Decreased Muscle Mass Prior to and Following Chemotherapy Predicts Morbidity in Testicular Cancer Patients Undergoing Post-Chemotherapy Retroperitoneal Lymph Node Dissection
    Baky, Fady J.
    Howard, Jeffrey M.
    Ashbrook, Caleb
    Jafri, Farzan
    Chertack, Nathan
    Woldu, Solomon
    Margulis, Vitaly
    Bagrodia, Aditya
    CLINICAL GENITOURINARY CANCER, 2022, 20 (06) : E460 - E464
  • [22] Pathologic findings and therapeutic outcome of desperation post-chemotherapy retroperitoneal lymph node dissection in advanced germ cell cancer
    Beck, SDW
    Foster, RS
    Bihrle, R
    Einhorn, LH
    Donohue, JP
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2005, 23 (06) : 423 - 430
  • [23] Additional surgical procedures and perioperative morbidity in post-chemotherapy retroperitoneal lymph node dissection for metastatic testicular cancer in two intermediate volume hospitals
    Joost M. Blok
    Richard P. Meijer
    Henk G. van der Poel
    Axel Bex
    Jeanette van Vooren
    Japke J. van Urk
    Simon Horenblas
    J. L. H. Ruud Bosch
    World Journal of Urology, 2021, 39 : 839 - 846
  • [24] Robotic retroperitoneal lymph node dissection for primary and post-chemotherapy testis cancer
    G. J. Nason
    K. Kuhathaas
    L. Anson-Cartwright
    M. A. S. Jewett
    M. O’Malley
    J. Sweet
    A. Hansen
    P. Bedard
    P. Chung
    E. Hahn
    P. Warde
    R. J. Hamilton
    Journal of Robotic Surgery, 2022, 16 : 369 - 375
  • [25] Post-chemotherapy robotic retroperitoneal lymph node dissection (RRPLND) in testicular cancer
    Kamel, Mohamed H.
    Jackson, C. Mark
    Moore, John T.
    Heshmat, Samy M.
    Bissada, Nabil K.
    JOURNAL OF ROBOTIC SURGERY, 2012, 6 (04) : 359 - 362
  • [26] Post-chemotherapy robotic retroperitoneal lymph node dissection (RRPLND) in testicular cancer
    Mohamed H. Kamel
    C. Mark Jackson
    John T. Moore
    Samy M. Heshmat
    Nabil K. Bissada
    Journal of Robotic Surgery, 2012, 6 (4) : 359 - 362
  • [27] Outcomes of the management of post-chemotherapy retroperitoneal lymph node dissection-associated anejaculation
    Hsiao, Wayland
    Deveci, Serkan
    Mulhall, John P.
    BJU INTERNATIONAL, 2012, 110 (08) : 1196 - 1200
  • [28] Extraperitoneal laparoscopic retroperitoneal lymph node dissection after chemotherapy for nonseminomatous testicular germ-cell tumor: surgical and oncological outcomes
    Arai, Yoichi
    Kaiho, Yasuhiro
    Yamada, Shigeyuki
    Saito, Hideo
    Mitsuzuka, Koji
    Yamashita, Shinichi
    Namiki, Shunichi
    Nakagawa, Haruo
    Ishidoya, Shigeto
    Ito, Akihiro
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2012, 44 (05) : 1389 - 1395
  • [29] Postchemotherapy Laparoscopic Retroperitoneal Lymph Node Dissection for Low-volume, Stage II, Nonseminomatous Germ Cell Tumor: First 100 Patients
    Steiner, Hannes
    Leonhartsberger, Nicolai
    Stoehr, Brigitte
    Peschel, Reinhard
    Pichler, Renate
    EUROPEAN UROLOGY, 2013, 63 (06) : 1013 - 1017
  • [30] Laparoskopisch retroperitoneale Lymphadenektomie bei Low-volume-Keimzelltumoren nach ChemotherapieEin Verfahren zur Verringerung der MorbiditätPost-chemotherapy laparoscopic retroperitoneal lymph node dissection in low volume residual germ cell cancerA technique to reduce morbidity
    S. Aufderklamm
    T. Todenhöfer
    J. Hennenlotter
    G. Gakis
    J. Mischinger
    J. Mundhenk
    M. Germann
    A. Stenzl
    C. Schwentner
    Der Urologe, 2013, 52 (8): : 1097 - 1103